Related Experiment Videos
Ceftazidime vs. standard therapy for pediatric meningitis: therapeutic, pharmacologic and epidemiologic observations
Insights
Ceftazidime (CZ) effectively treated bacterial meningitis in children, showing favorable outcomes compared to conventional treatments. This antibiotic demonstrated potent antimicrobial activity and a good safety profile in pediatric patients.
Area of Science:
- Pediatric Infectious Diseases
- Clinical Pharmacology
- Bacteriology
Background:
- Bacterial meningitis remains a significant cause of childhood morbidity and mortality.
- Conventional treatments for bacterial meningitis have limitations and potential toxicities.
- Novel antimicrobial agents are needed for effective pediatric meningitis management.
Purpose of the Study:
- To evaluate the efficacy and safety of ceftazidime (CZ) compared to conventional chloramphenicol and ampicillin (CA) for treating bacterial meningitis in children.
- To assess the in vitro activity of CZ against common meningitis pathogens.
- To determine the pharmacokinetic profile of CZ in pediatric patients with meningitis.
Main Methods:
- A comparative study involving 100 pediatric patients (1 month to 15 years) with suspected bacterial meningitis.
- Patients received either ceftazidime (150 mg/kg/day divided every 8 hours) or conventional therapy (chloramphenicol and ampicillin).
- Cerebrospinal fluid (CSF) and blood cultures, latex agglutination tests, antimicrobial susceptibility testing, and pharmacokinetic sampling were performed.
Main Results:
- Ceftazidime demonstrated broad-spectrum activity, inhibiting common meningitis pathogens including Haemophilus influenzae, Streptococcus pneumoniae, and Neisseria meningitidis.
- In patients surviving >24 hours, ceftazidime treatment resulted in a 10% mortality rate, 2% improvement, and 88% cure rate.
- Overall mortality rates were comparable between ceftazidime (20%) and conventional therapy (21%), with no significant ceftazidime-related toxicities.
- Neurologic sequelae rates were low and similar between treatment groups (5% for CZ vs. 4% for CA).
Conclusions:
- Ceftazidime is an effective and well-tolerated alternative for treating bacterial meningitis in pediatric patients.
- CZ exhibits favorable pharmacokinetic properties, achieving therapeutic concentrations in CSF.
- Ceftazidime offers a promising therapeutic option for pediatric meningitis, comparable to conventional treatments with a good safety profile.
Abstract:
One hundred patients ages 1 month to 15 years received either ceftazidime (CZ) at a dose of 150 mg/kg/day divided every 8 hours or conventional treatment with chloramphenicol and ampicillin (CA). Seventy-eight had isolates recovered from the cerebrospinal fluid: 40 (51%) were Haemophilus influenzae (all ampicillin-susceptible); 16 (21%) were Streptococcus pneumoniae; 14 (18%) were Neisseria meningitidis; 3 (4%) were salmonellae; 1 (2%) was Pseudomonas; and 1 (2%) was Group B Streptococcus. Six patients with negative cerebrospinal fluid culture had positive latex agglutination (two H. influenzae, three N. meningitidis, one S. pneumoniae). Sixty-one patients had positive blood cultures. CZ inhibited 100% of H. influenzae at 0.78 micrograms/ml, S. pneumoniae at 0.39, N. meningitidis at 0.04 and salmonellae at 0.39 micrograms/ml. The mean peak serum concentration of CZ was 36.4 micrograms/ml with a mean cerebrospinal fluid level of 7.4 micrograms/ml. If one eliminates from the statistics those patients who died less than or equal to 24 hours after admission, five (10%) of 49 patients treated with CZ died, one (2%) improved and 43 (88%) were cured. Overall 29 patients died, 12 receiving CZ (20%) and 8 receiving CA (21%). There were no significant CZ-related toxicities. Gross neurologic sequelae were noted in 5% of 38 CZ patients and 4% of 28 CA patients. CZ compared favorably to CA for treatment of meningitis.